Revenue by Product | Investor Relations | CHUGAI PHARMACEUTICAL CO., LTD.

* This page is being updated.

(Billions of Yen)

					2006	2007	2008	2009	2010
Sales					326.1	332.9	321.8	419.1	375.6
	Excl.Tamiflu®				288.2	294.3	313.4	342.9	357.4
		Domestic			259.8	263.1	279.9	309.3	324.4
			Oncology field		67.8	74.0	102.3	123.7	141.2
				Avastin®	-	3.5	20.1	34.9	52.6
				Herceptin®	14.5	16.1	23.7	29.7	25.3
				Rituxan®	18.0	18.6	20.5	21.1	23.0
				Xeloda®	2.5	2.7	4.8	6.6	10.7
				Neutrogin®	12.0	12.6	12.0	11.3	10.4
				Tarceva®	-	0.2	4.5	5.8	7.9
				Kytril®	12.9	13.6	10.9	8.6	5.5
				Femara®	0.3	1.0	1.7	2.4	3.2
				Other products	7.6	5.6	4.1	3.3	2.5
			Bone and joint diseases field		42.2	46.6	50.0	57.6	62.6
				Evista®	13.4	16.0	16.5	17.9	18.7
				Actemra®	0.4	0.5	3.4	8.4	14.1
				Suvenyl®	9.1	11.0	12.0	13.7	13.6
				Alfarol®	14.6	14.3	13.7	13.6	12.3
				Other products	4.6	4.8	4.5	3.9	4.0
			Renal diseases field		76.8	69.6	61.3	61.0	57.4
				Epogin®	63.4	54.8	44.9	44.4	40.0
				Oxarol®	7.6	8.7	10.0	10.6	12.0
				Renagel®	5.0	5.6	5.7	5.3	4.9
				Other products	0.7	0.5	0.7	0.7	0.5
			Transplant, Immunology & Infectious diseases field		14.5	17.7	24.0	26.2	25.8
				Pegasys®	5.8	6.3	9.7	11.1	10.5
				Copegus®	-	2.0	4.2	4.9	4.5
				Rocephin®	5.5	5.7	5.9	5.5	5.4
				CellCept®	3.0	3.5	4.0	4.4	5.2
				Other products	0.3	0.3	0.3	0.3	0.3
			Others field		58.4	55.1	42.3	40.9	37.4
				Sigmart®	15.4	15.2	15.0	14.7	13.0
				SA products	12.9	11.2	-	-	-
				Other products	30.1	28.8	27.3	26.3	24.4
			Overseas		28.4	31.2	33.5	33.6	33.0
				Neutrogin®	24.2	26.6	25.9	21.3	17.0
				Actemra®	-	-	3.8	8.9	12.7
				Sigmart®	2.6	2.8	2.0	1.9	2.2
				Other products	1.6	1.9	1.7	1.5	1.2
	Tamiflu®				38.0	38.7	8.4	76.2	18.2
		Ordinary sales			13.6	10.2	7.1	36.2	1.6
		Govt. stockpile etc.			24.4	28.5	1.3	40.0	16.6
Other operating revenues					-	11.9	5.1	9.8	3.9
Revenues (total)					326.1	344.8	326.9	428.9	379.5
		Domestic			297.7	308.4	293.1	392.6	342.9
		Overseas			28.4	36.4	33.8	36.4	36.6